SCA
BSX icon

Snowden Capital Advisors’s Boston Scientific BSX Stock Holding History

Snowden Capital Advisors’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$908K Sell
14,467
-3,790
-21% -$303K 0.02% 564
2025
Q4 		$1.74M Sell
18,257
-4,687
-20% -$460K 0.05% 368
2025
Q3 		$2.24M Buy
22,944
+2,551
+13% +$264K 0.06% 299
2025
Q2 		$2.19M Sell
20,393
-2,864
-12% -$290K 0.06% 286
2025
Q1 		$2.35M Buy
23,257
+1,860
+9% +$187K 0.08% 266
2024
Q4 		$1.91M Sell
21,397
-2,314
-10% -$204K 0.06% 313
2024
Q3 		$1.99M Sell
23,711
-486
-2% -$38.3K 0.06% 323
2024
Q2 		$1.86M Sell
24,197
-471
-2% -$34.5K 0.06% 331
2024
Q1 		$1.69M Buy
24,668
+3,247
+15% +$209K 0.05% 360
2023
Q4 		$1.24M Sell
21,421
-1,949
-8% -$104K 0.05% 388
2023
Q3 		$1.23M Sell
23,370
-578
-2% -$30.3K 0.05% 361
2023
Q2 		$1.3M Sell
23,948
-4,485
-16% -$234K 0.05% 391
2023
Q1 		$1.42M Buy
28,433
+3,392
+14% +$160K 0.06% 368
2022
Q4 		$1.16M Sell
25,041
-247
-1% -$10.7K 0.05% 418
2022
Q3 		$979K Buy
25,288
+207
+0.8% +$8.3K 0.04% 429
2022
Q2 		$934K Buy
25,081
+878
+4% +$35.7K 0.04% 436
2022
Q1 		$1.07M Buy
24,203
+12,096
+100% +$524K 0.04% 411
2021
Q4 		$514K Sell
12,107
-11,631
-49% -$489K 0.03% 445
2021
Q3 		$1.03M Buy
23,738
+1,104
+5% +$48.8K 0.05% 363
2021
Q2 		$968K Sell
22,634
-1,160
-5% -$48.8K 0.05% 383
2021
Q1 		$920K Buy
23,794
+7,538
+46% +$285K 0.05% 365
2020
Q4 		$584K Buy
16,256
+426
+3% +$15.4K 0.04% 405
2020
Q3 		$605K Buy
15,830
+427
+3% +$16.5K 0.05% 350
2020
Q2 		$541K Buy
15,403
+1,471
+11% +$53K 0.05% 357
2020
Q1 		$455K Buy
13,932
+1,720
+14% +$67.2K 0.05% 355
2019
Q4 		$552K Buy
12,212
+776
+7% +$32.5K 0.05% 372
2019
Q3 		$465K Buy
11,436
+526
+5% +$22.3K 0.05% 356
2019
Q2 		$469K Sell
10,910
-3
-0% -$115 0.05% 337
2019
Q1 		$419K Buy
+10,913
New +$417K 0.05% 344

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Snowden Capital Advisors's BSX Position: Q1 2026 in Review

Snowden Capital Advisors reduced its Boston Scientific (BSX) stake by 21% in Q1 2026, selling an estimated $303K and leaving 14,467 shares worth $908K. The position accounts for 0.02% of the portfolio, ranked #564.

Snowden Capital Advisors first reported a position in BSX in Q1 2019 and has held it in 29 quarters since. The position peaked at $2.35M in Q1 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Snowden Capital Advisors held 14,467 shares of Boston Scientific worth $908K as of Q1 2026.
  • Snowden Capital Advisors sold 3,790 Boston Scientific shares in Q1 2026, an estimated $303K.
  • Boston Scientific made up 0.02% of Snowden Capital Advisors's portfolio in Q1 2026, its #564 holding.
  • Snowden Capital Advisors first reported a position in Boston Scientific in Q1 2019 and has held it in 29 quarters since.
  • Snowden Capital Advisors's Boston Scientific position peaked at $2.35M in Q1 2025.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.